KDR and nonpapillary renal cell carcinoma: The standard first-line systematic treatment for metastatic or advanced ccRCC includes tyrosine kinase inhibitors (TKIs) such as sunitinib or pazopanib that target the vascular endothelial growth factor receptor (VEGFR) (Motzer et al., 2007; Escudier et al., 2019; Porta et al., 2019).